{
    "root": "8b236f4c-7654-49fe-bca9-ab947b72a1fd",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Myalept",
    "value": "20240325",
    "ingredients": [
        {
            "name": "Metreleptin",
            "code": "TL60C27RLH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09046"
        },
        {
            "name": "Glycine",
            "code": "TE7660XO1C",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15428"
        },
        {
            "name": "Sucrose",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "Polysorbate 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "Glutamic Acid",
            "code": "3KX376GY7L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_18237"
        }
    ],
    "indications": {
        "text": "myalept leptin analog indicated adjunct diet replacement therapy treat complications leptin deficiency patients congenital acquired generalized lipodystrophy . ( 1 ) limitations safety effectiveness myalept treatment complications partial lipodystrophy established . ( 1 ) safety effectiveness myalept treatment liver disease , including nonalcoholic steatohepatitis ( nash ) , established . ( 1 ) myalept indicated patients hiv-related lipodystrophy . ( 1 ) myalept indicated patients metabolic disease , without concurrent evidence generalized lipodystrophy . ( 1 )",
        "doid_entities": [
            {
                "text": "acquired generalized lipodystrophy (DOID:0080300)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080300"
            },
            {
                "text": "lipodystrophy (DOID:811)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_811"
            },
            {
                "text": "partial lipodystrophy (DOID:0080299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080299"
            },
            {
                "text": "liver disease (DOID:409)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_409"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "nonalcoholic steatohepatitis (DOID:0080547)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080547"
            },
            {
                "text": "metabolic disease (DOID:0014667)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0014667"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "administer subcutaneous injection daily lyophilized cake reconstituted bacteriostatic water injection ( bwfi ) preservative-free sterile water injection ( wfi ) . ( 2.1 ) recommended daily dosages : body weight 40 kg less : starting dose 0.06 mg/kg/day , increase decrease 0.02 mg/kg maximum daily dose 0.13 mg/kg . ( 2.1 ) males greater 40 kg body weight : starting dose 2.5 mg/day , increase decrease 1.25 mg 2.5 mg/day maximum dose 10 mg/day . ( 2.1 ) females greater 40 kg body weight : starting dose 5 mg/day , increase decrease 1.25 mg 2.5 mg/day maximum dose 10 mg/day . ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "general obesity associated congenital leptin deficiency . ( 4.1 ) hypersensitivity metreleptin . ( 4.2 )",
    "indications_original": "MYALEPT is a leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. ( 1 ) Limitations of Use The safety and effectiveness of MYALEPT for the treatment of complications of partial lipodystrophy have not been established. ( 1 ) The safety and effectiveness of MYALEPT for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established. ( 1 ) MYALEPT is not indicated for use in patients with HIV-related lipodystrophy. ( 1 ) MYALEPT is not indicated for use in patients with metabolic disease, without concurrent evidence of generalized lipodystrophy. ( 1 )",
    "contraindications_original": "Administer as a subcutaneous injection once daily after the lyophilized cake is reconstituted with Bacteriostatic Water for Injection (BWFI) or preservative-free sterile Water for Injection (WFI). ( 2.1 ) The recommended daily dosages are: Body weight 40 kg or less: starting dose 0.06 mg/kg/day, increase or decrease by 0.02 mg/kg to a maximum daily dose of 0.13 mg/kg. ( 2.1 ) Males greater than 40 kg body weight: starting dose 2.5 mg/day, increase or decrease by 1.25 mg to 2.5 mg/day to a maximum dose of 10 mg/day. ( 2.1 ) Females greater than 40 kg body weight: starting dose 5 mg/day, increase or decrease by 1.25 mg to 2.5 mg/day to a maximum dose of 10 mg/day. ( 2.1 )",
    "adverseReactions_original": "General obesity not associated with congenital leptin deficiency. ( 4.1 ) Hypersensitivity to metreleptin. ( 4.2 )",
    "drug": [
        {
            "name": "Myalept",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09046"
        }
    ]
}